In an interview with PharmaShots, Daniel A. de Boer of ProQR shared his views on P-II/III pivotal trial of Sepofarsen to treat the root cause of a rare eye disease, […]readmore
Tags : First Treatment
Shots: The FDA’s approval is based on P-III INBUILD study assessing Ofev (150mg, bid) vs PBO in 663 patients with chronic fibrosing ILDs with a progressive phenotype for 52wks. at […]readmore